Table 2.
Outcomes at 1 year (percentage of patients) for appropriate care with and without Hylan G-F 20 in knee OA
| Outcomes at 1 year | Appropriate care plus Hylan G-F 20 (n=127) | Appropriate care alone (n=128) | Relative benefit increase (95% CI) | NNT (95% CI) |
|---|---|---|---|---|
| Improved WOMAC pain | 69% | 40% | 72% (36–121) | 3 (3–6) |
| Improved WOMAC pain and stiffness or physical functioning | 62% | 35% | 77% (36–134) | 4 (3–7) |
| Improved OA in study knee | 73% | 27% | 168% (101–265) | 2 (2–3) |
| Improved OA in all joints | 38% | 17% | 120% (43–243) | 5 (3–10) |
| Absence of side effects | 62% | 41% | 53% (20–98) | 5 (3–11) |
| cPatients reporting medication use: | ||||
| Intra-articular corticosteroid injections in study knee | 14% | 70%a | ||
| Intra-articular corticosteroid injections in other knee | 6% | 27%a | ||
| Oral NSAIDS | 65% | 79%b |
Notes:
a
P<0.0001;
b
P=0.0062.
c
Part data from Raynauld et al.31 Partially adapted with permission from Symmons D. Hylan G-F 20 was safe and effective in knee osteoarthritis and had a relatively low cost-utility ratio. ACP J Club. 2003; 138(1):20.32
Abbreviations: OA, osteoarthritis; NNT, number needed to treat; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; NSAIDs, nonsteroidal anti-inflammatory drugs; CI, confidence interval.